Login to Your Account



Arena Rises on Lorcaserin FDA Briefing Docs Ahead of EMDAC

By Catherine Shaffer
Staff Writer

Wednesday, May 9, 2012

Briefing documents released in advance of Thursday's meeting of the FDA's Endocrinological and Metabolic Drugs Advisory Committee (EMDAC) suggested Arena Pharmaceuticals Inc. may have allayed many of the agency's concerns about the safety of its weight loss drug Lorqess (lorcaserin).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription